09.26.25 -- Redefining Heart Failure Treatment With Precision Autologous Cell Therapy

Project Optimus and adaptive trial designs are reshaping oncology development, improving patient outcomes, and streamlining approval pathways.

Review new transparency requirements for NIH-funded institutions engaged in research involving r/sNA molecules and regulations for Institutional Biosafety Committees (IBCs).

While GLP-1 receptor agonists offer significant health benefits, proactive eye care and vigilance are essential to mitigate the risk of irreversible ocular conditions.

Learn how AI is redefining the development pipeline for neurodegenerative diseases (NDDs), offering a path forward in the quest for effective, disease-modifying treatments.

Explore the landscape of dermatological drug development through a comprehensive framework for rational early-phase dermatological trials, centered around five foundational pillars.

The I-SPY 2 trial represents a groundbreaking approach in oncology, with a key component of the trial's success being the integration of EHR with EDC leveraging a technology approach.

This presentation explores how and when to initiate IND activities, highlighting that sponsors can strategically open an IND to access FDA guidance and enable U.S. clinical trials.

Emerging clinical trial site networks enable faster site activation, scalable operations, and improved patient recruitment by embedding trials directly in patient communities.

Vendor selection in clinical trials is a pivotal process. Explore ten widespread inefficiencies in the current approach and how you can resolve them.

Drug manufacturers seek packaging that maintains integrity during processing and freezing, scales up to larger volumes easily, and remains robust throughout the temperature-controlled supply chain.